399 related articles for article (PubMed ID: 9703784)
21. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
22. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
25. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
26. Amifostine and combined-modality therapeutic approaches.
Mehta MP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
[TBL] [Abstract][Full Text] [Related]
27. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
28. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
30. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Mangoni M; Yue X; Morin C; Violot D; Frascogna V; Tao Y; Opolon P; Castaing M; Auperin A; Biti G; Barritault D; Vozenin-Brotons MC; Deutsch E; Bourhis J
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1242-50. PubMed ID: 19545790
[TBL] [Abstract][Full Text] [Related]
31. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
[TBL] [Abstract][Full Text] [Related]
32. Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes.
Uma Devi P; Prasanna PG
Radiat Res; 1990 Nov; 124(2):165-70. PubMed ID: 2174174
[TBL] [Abstract][Full Text] [Related]
33. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
36. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
[TBL] [Abstract][Full Text] [Related]
37. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
38. Future development of amifostine in cancer treatment.
Alberts DS; Bleyer WA
Semin Oncol; 1996 Aug; 23(4 Suppl 8):90-9. PubMed ID: 8783674
[TBL] [Abstract][Full Text] [Related]
39. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.
Andreassen CN; Grau C; Lindegaard JC
Semin Radiat Oncol; 2003 Jan; 13(1):62-72. PubMed ID: 12520465
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]